Logo

Hoth Therapeutics Signs a License Agreement with UMB and Isoprene Pharmaceuticals

Share this

Hoth Therapeutics Signs a License Agreement with UMB and Isoprene Pharmaceuticals

Shots: 

  • Hoth Therapeutics to get exclusive rights to evaluate UMB’s retinamides (RAMBAs) with an option to license the product to develop & commercialize therapies in the fields of dermatology and oncology 
  • The focus of the agreement is to develop UMB’s novel retinamide Retinoic acid metabolism blocking agents (RAMBAs) therapies for cancer and dermatological diseases
  • UMB’s RAMBAs are anticancer agents works against ATRA in cells providing therapeutic benefits to dermatological diseases including acne- eczema- psoriasis- cold sores- wounds- burns- sunburn- ichthyosis- skin cancer- and Kaposi's Sarcoma

Ref: Hoth Therapeutics | Image: Plexuss

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions